"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
DOSAGE AND ADMINISTRATION
Dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered in elderly patients with renal impairment (creatinine clearance ≤ 70 mL/min/1.73m²). Final dose adjustment should be based upon integration of clinical efficacy and safety considerations. (See CLINICAL PHARMACOLOGY and PRECAUTIONS).
Patients with Renal Impairment
In subjects with renal impairment (creatinine clearance ≤ 70 mL/min/1.73m²), dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered. (See CLINICAL PHARMACOLOGY and PRECAUTIONS).
Capsules, 300 mg
Usual Adult Dosage
Store at 25°C (77°F). Excursions permitted to 15–30°C (59–86°F).
[See USP Controlled Room Temperature]
Capsules, 300 mg trimethobenzamide hydrochloride each, bottles of 100 NDC 61570-079-01 300 mg 100's
Prescribing Information as of April 2008. Distributed By: Monarch Pharmaceuticals, Inc., Bristol, TN 37620 (A wholly owned subsidiary of King Pharmaceuticals, Inc.) Manufactured By: King Pharmaceuticals, Inc., Bristol, TN 37620. FDA revision date: 12/2/2008This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/23/2009
Additional Tigan Information
Tigan - User Reviews
Tigan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.